{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T15:30:45Z","timestamp":1795015845401,"version":"4.10.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003100","name":"F\u00e9d\u00e9ration fran\u00e7aise de cardiologie","doi-asserted-by":"crossref","award":["Bourse de Master 2 et allocation de recherche"],"award-info":[{"award-number":["Bourse de Master 2 et allocation de recherche"]}],"id":[{"id":"10.13039\/501100003100","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003100","name":"F\u00e9d\u00e9ration fran\u00e7aise de cardiologie","doi-asserted-by":"crossref","award":["Bourse de Master 2 et allocation de recherche"],"award-info":[{"award-number":["Bourse de Master 2 et allocation de recherche"]}],"id":[{"id":"10.13039\/501100003100","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Synthetized by the liver and metabolized by the gut microbiota, BA are involved in metabolic liver diseases that are associated with cardiovascular disorders. Animal models of atheroma documented a powerful anti-atherosclerotic effect of bile acids (BA). This prospective study examined whether variations in circulating BA are predictive of coronary artery disease (CAD) in human. Consecutive patients undergoing coronary angiography were enrolled. Circulating and fecal BA were measured by high pressure liquid chromatography and tandem mass spectrometry. Of 406 screened patients, 80 were prospectively included and divided in two groups with (<jats:italic>n<\/jats:italic>\u2009=\u200945) and without (<jats:italic>n<\/jats:italic>\u2009=\u200935) CAD. The mean serum concentration of total BA was twice lower in patients with, versus without CAD (<jats:italic>P<\/jats:italic>\u2009=\u20090.005). Adjusted for gender and age, this decrease was an independent predictor of CAD. In a subgroup of 17 patients, statin therapy doubled the serum BA concentration. Decreased serum concentrations of BA were predictors of CAD in humans. A subgroup analysis showed a possible correction by statins. With respect to the anti-atherosclerotic effect of BA in animal models, and their role in human lipid metabolism, this study describe a new metabolic disturbance associated to CAD in human.\n<\/jats:p>","DOI":"10.1038\/s41598-021-02144-y","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T11:02:58Z","timestamp":1637578978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Circulating bile acids concentration is predictive of coronary artery disease in human"],"prefix":"10.1038","volume":"11","author":[{"given":"Caroline","family":"Chong Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Duboc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Rainteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydie","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Seksik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e8le","family":"Bellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendy","family":"Abdoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na\u00efm","family":"Bouazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Treluyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malika","family":"Saadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Wahbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heithem","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Coffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Bado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maude","family":"Le Gall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Varenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Duboc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"2144_CR1","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","volume":"114","author":"JF Bentzon","year":"2014","unstructured":"Bentzon, J. F., Otsuka, F., Virmani, R. & Falk, E. Mechanisms of plaque formation and rupture. Circ. Res. 114, 1852\u20131866 (2014).","journal-title":"Circ. Res."},{"key":"2144_CR2","doi-asserted-by":"crossref","unstructured":"Stewart, J., Manmathan, G. & Wilkinson, P. Primary prevention of cardiovascular disease: A review of contemporary guidance and literature. JRSM Cardiovasc. Dis. 6 (2017).","DOI":"10.1177\/2048004016687211"},{"key":"2144_CR3","first-page":"646","volume":"10","author":"M Stepanova","year":"2012","unstructured":"Stepanova, M. & Younossi, Z. M. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 10, 646\u2013650 (2012).","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"2144_CR4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","volume":"65","author":"SM Francque","year":"2016","unstructured":"Francque, S. M., van der Graaff, D. & Kwanten, W. J. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J. Hepatol. 65, 425\u2013443 (2016).","journal-title":"J. Hepatol."},{"key":"2144_CR5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2019.01.029","volume":"282","author":"RD Santos","year":"2019","unstructured":"Santos, R. D., Valenti, L. & Romeo, S. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis 282, 110\u2013120 (2019).","journal-title":"Atherosclerosis"},{"key":"2144_CR6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.01.055","author":"O Ch\u00e1vez-Talavera","year":"2017","unstructured":"Ch\u00e1vez-Talavera, O., Tailleux, A., Lefebvre, P. & Staels, B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia and NAFLD. Gastroenterology https:\/\/doi.org\/10.1053\/j.gastro.2017.01.055 (2017).","journal-title":"Gastroenterology"},{"key":"2144_CR7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pharmthera.2018.04.005","volume":"190","author":"Q Yu","year":"2018","unstructured":"Yu, Q., Jiang, Z. & Zhang, L. Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease. Pharmacol. Ther. 190, 81\u201390 (2018).","journal-title":"Pharmacol. Ther."},{"key":"2144_CR8","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cmet.2011.11.006","volume":"14","author":"TWH Pols","year":"2011","unstructured":"Pols, T. W. H. et al. TGR5 Activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 14, 747\u2013757 (2011).","journal-title":"Cell Metab."},{"key":"2144_CR9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.metabol.2010.03.006","volume":"60","author":"SC Kalhan","year":"2011","unstructured":"Kalhan, S. C. et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 60, 404\u2013413 (2011).","journal-title":"Metabolism"},{"key":"2144_CR10","doi-asserted-by":"crossref","first-page":"104437","DOI":"10.1016\/j.yexmp.2020.104437","volume":"114","author":"S Yamamoto","year":"2020","unstructured":"Yamamoto, S. et al. Bile acids aggravate nonalcoholic steatohepatitis and cardiovascular disease in SHRSP5\/Dmcr rat model. Exp. Mol. Pathol. 114, 104437 (2020).","journal-title":"Exp. Mol. Pathol."},{"key":"2144_CR11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5551\/jat1994.3.52","volume":"3","author":"K Uchida","year":"1996","unstructured":"Uchida, K. et al. Altered bile acid metabolism related to atherosclerosis in alloxan diabetic rats. J. Atheroscler. Thromb. 3, 52\u201358 (1996).","journal-title":"J. Atheroscler. Thromb."},{"key":"2144_CR12","doi-asserted-by":"crossref","unstructured":"de Aguiar Vallim, T. Q., Tarling, E. J. & Edwards, P. A. Pleiotropic roles of bile acids in metabolism. Cell Metab. 17, 657\u2013669 (2013).","DOI":"10.1016\/j.cmet.2013.03.013"},{"key":"2144_CR13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/19490976.2015.1127483","volume":"7","author":"JM Ridlon","year":"2016","unstructured":"Ridlon, J. M., Harris, S. C., Bhowmik, S., Kang, D.-J. & Hylemon, P. B. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes 7, 22\u201339 (2016).","journal-title":"Gut Microbes"},{"key":"2144_CR14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","volume":"3","author":"H Wang","year":"1999","unstructured":"Wang, H., Chen, J., Hollister, K., Sowers, L. C. & Forman, B. M. Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR. Mol. Cell 3, 543\u2013553 (1999).","journal-title":"Mol. Cell"},{"key":"2144_CR15","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0006-291X(02)02550-0","volume":"298","author":"T Maruyama","year":"2002","unstructured":"Maruyama, T. et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298, 714\u2013719 (2002).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2144_CR16","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.3109\/00365521.2013.833647","volume":"48","author":"M Werling","year":"2013","unstructured":"Werling, M. et al. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scand. J. Gastroenterol. 48, 1257\u20131264 (2013).","journal-title":"Scand. J. Gastroenterol."},{"key":"2144_CR17","doi-asserted-by":"crossref","unstructured":"Duboc, H., Tach\u00e9, Y. & Hofmann, A. F. The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver 46, 302\u2013312 (2014).","DOI":"10.1016\/j.dld.2013.10.021"},{"key":"2144_CR18","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","volume":"151","author":"FJ Gonzalez","year":"2016","unstructured":"Gonzalez, F. J., Jiang, C. & Patterson, A. D. An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease. Gastroenterology 151, 845\u2013859 (2016).","journal-title":"Gastroenterology"},{"key":"2144_CR19","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet Lond. Engl. 385, 956\u2013965 (2015).","journal-title":"Lancet Lond. Engl."},{"key":"2144_CR20","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1194\/jlr.M500390-JLR200","volume":"46","author":"EA Hanniman","year":"2005","unstructured":"Hanniman, E. A., Lambert, G., McCarthy, T. C. & Sinal, C. J. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 46, 2595\u20132604 (2005).","journal-title":"J. Lipid Res."},{"key":"2144_CR21","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1194\/jlr.M800619-JLR200","volume":"50","author":"HB Hartman","year":"2009","unstructured":"Hartman, H. B. et al. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-\/- and apoE-\/- mice. J. Lipid Res. 50, 1090\u20131100 (2009).","journal-title":"J. Lipid Res."},{"key":"2144_CR22","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature04330","volume":"439","author":"M Watanabe","year":"2006","unstructured":"Watanabe, M. et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439, 484\u2013489 (2006).","journal-title":"Nature"},{"key":"2144_CR23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1042\/EBC20160052","volume":"60","author":"J Fiamoncini","year":"2016","unstructured":"Fiamoncini, J., Curi, R. & Daniel, H. Metabolism of bile acids in the post-prandial state. Essays Biochem. 60, 409\u2013418 (2016).","journal-title":"Essays Biochem."},{"key":"2144_CR24","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/0014-5793(88)80944-X","volume":"239","author":"M Axelson","year":"1988","unstructured":"Axelson, M., Aly, A. & Sj\u00f6vall, J. Levels of 7 alpha-hydroxy-4-cholesten-3-one in plasma reflect rates of bile acid synthesis in man. FEBS Lett. 239, 324\u2013328 (1988).","journal-title":"FEBS Lett."},{"key":"2144_CR25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/0014-5793(91)80688-Y","volume":"284","author":"M Axelson","year":"1991","unstructured":"Axelson, M., Bj\u00f6rkhem, I., Reihn\u00e9r, E. & Einarsson, K. The plasma level of 7 alpha-hydroxy-4-cholesten-3-one reflects the activity of hepatic cholesterol 7 alpha-hydroxylase in man. FEBS Lett. 284, 216\u2013218 (1991).","journal-title":"FEBS Lett."},{"key":"2144_CR26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jcmgh.2020.02.005","volume":"10","author":"V Voronova","year":"2020","unstructured":"Voronova, V. et al. A physiology-based model of bile acid distribution and metabolism under healthy and pathologic conditions in human beings. Cell. Mol. Gastroenterol. Hepatol. 10, 149\u2013170 (2020).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"2144_CR27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/apt.14219","volume":"46","author":"S Petta","year":"2017","unstructured":"Petta, S. et al. Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. Aliment. Pharmacol. Ther. 46, 617\u2013627 (2017).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2144_CR28","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/hep.26225","volume":"57","author":"LP Bechmann","year":"2013","unstructured":"Bechmann, L. P. et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatol. Baltim. Md 57, 1394\u20131406 (2013).","journal-title":"Hepatol. Baltim. Md"},{"key":"2144_CR29","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3748\/wjg.v24.i30.3361","volume":"24","author":"S Leoni","year":"2018","unstructured":"Leoni, S. et al. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J. Gastroenterol. 24, 3361\u20133373 (2018).","journal-title":"World J. Gastroenterol."},{"key":"2144_CR30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2019.11.026","volume":"292","author":"W Li","year":"2020","unstructured":"Li, W. et al. Fasting serum total bile acid level is associated with coronary artery disease, myocardial infarction and severity of coronary lesions. Atherosclerosis 292, 193\u2013200 (2020).","journal-title":"Atherosclerosis"},{"key":"2144_CR31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/hep.1840160317","volume":"16","author":"Y Calmus","year":"1992","unstructured":"Calmus, Y. et al. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatol. Baltim. Md 16, 719\u2013723 (1992).","journal-title":"Hepatol. Baltim. Md"},{"key":"2144_CR32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbrc.2008.04.171","volume":"372","author":"V Keitel","year":"2008","unstructured":"Keitel, V., Donner, M., Winandy, S., Kubitz, R. & H\u00e4ussinger, D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem. Biophys. Res. Commun. 372, 78\u201384 (2008).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2144_CR33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/0004563218817798","volume":"56","author":"ER McGlone","year":"2019","unstructured":"McGlone, E. R. & Bloom, S. R. Bile acids and the metabolic syndrome. Ann. Clin. Biochem. 56, 326\u2013337 (2019).","journal-title":"Ann. Clin. Biochem."},{"key":"2144_CR34","doi-asserted-by":"crossref","first-page":"H272","DOI":"10.1152\/ajpheart.01075.2008","volume":"296","author":"A Mencarelli","year":"2009","unstructured":"Mencarelli, A., Renga, B., Distrutti, E. & Fiorucci, S. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol. 296, H272-281 (2009).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2144_CR35","doi-asserted-by":"crossref","first-page":"e108270","DOI":"10.1371\/journal.pone.0108270","volume":"9","author":"S Miyazaki-Anzai","year":"2014","unstructured":"Miyazaki-Anzai, S., Masuda, M., Levi, M., Keenan, A. L. & Miyazaki, M. Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis. PLoS ONE 9, e108270 (2014).","journal-title":"PLoS ONE"},{"key":"2144_CR36","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","volume":"145","author":"S Mudaliar","year":"2013","unstructured":"Mudaliar, S. et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574-582.e1 (2013).","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"2144_CR37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000174548","volume":"76","author":"J Shepherd","year":"1989","unstructured":"Shepherd, J. Mechanism of action of bile acid sequestrants and other lipid-lowering drugs. Cardiology 76(Suppl 1), 65\u201371 (1989).","journal-title":"Cardiology"},{"key":"2144_CR38","first-page":"53","volume":"1","author":"T Sonnett","year":"2010","unstructured":"Sonnett, T., Robinson, J., Milani, P. & Campbell, R. K. Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children. Adolesc. Health Med. Ther. 1, 53\u201360 (2010).","journal-title":"Adolesc. Health Med. Ther."},{"key":"2144_CR39","doi-asserted-by":"crossref","unstructured":"Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol In Adults (Adult Treatment Panel III). JAMA 285, 2486\u20132497 (2001).","DOI":"10.1001\/jama.285.19.2486"},{"key":"2144_CR40","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1172\/JCI107100","volume":"51","author":"JT Garbutt","year":"1972","unstructured":"Garbutt, J. T. & Kenney, T. J. Effect of cholestyramine on bile acid metabolism in normal man. J. Clin. Invest. 51, 2781\u20132789 (1972).","journal-title":"J. Clin. Invest."},{"key":"2144_CR41","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/CIRCGENETICS.114.000952","volume":"8","author":"S Ross","year":"2015","unstructured":"Ross, S. et al. Effect of bile acid sequestrants on the risk of cardiovascular events: a mendelian randomization analysis. Circ. Cardiovasc. Genet. 8, 618\u2013627 (2015).","journal-title":"Circ. Cardiovasc. Genet."},{"key":"2144_CR42","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.tcm.2019.01.001","volume":"29","author":"SO Almeida","year":"2019","unstructured":"Almeida, S. O. & Budoff, M. Effect of statins on atherosclerotic plaque. Trends Cardiovasc. Med. 29, 451\u2013455 (2019).","journal-title":"Trends Cardiovasc. Med."},{"key":"2144_CR43","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","volume":"63","author":"P Dongiovanni","year":"2015","unstructured":"Dongiovanni, P. et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J. Hepatol. 63, 705\u2013712 (2015).","journal-title":"J. Hepatol."},{"key":"2144_CR44","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1007\/s10620-015-4000-6","volume":"61","author":"P Blais","year":"2016","unstructured":"Blais, P., Lin, M., Kramer, J. R., El-Serag, H. B. & Kanwal, F. Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. Dig. Dis. Sci. 61, 1714\u20131720 (2016).","journal-title":"Dig. Dis. Sci."},{"key":"2144_CR45","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","volume":"21","author":"K Kargiotis","year":"2015","unstructured":"Kargiotis, K. et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J. Gastroenterol. 21, 7860\u20137868 (2015).","journal-title":"World J. Gastroenterol."},{"key":"2144_CR46","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1194\/jlr.M053124","volume":"55","author":"ZD Fu","year":"2014","unstructured":"Fu, Z. D., Cui, J. Y. & Klaassen, C. D. Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice. J. Lipid Res. 55, 2576\u20132586 (2014).","journal-title":"J. Lipid Res."},{"key":"2144_CR47","doi-asserted-by":"crossref","unstructured":"Charach, G., Rabinovich, A., Argov, O., Weintraub, M. & Rabinovich, P. The role of bile acid excretion in atherosclerotic coronary artery disease. Int. J. Vasc. Med. 2012 (2012).","DOI":"10.1155\/2012\/949672"},{"key":"2144_CR48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.atherosclerosis.2019.12.010","volume":"293","author":"G Charach","year":"2020","unstructured":"Charach, G. et al. Reduced bile acid excretion is an independent risk factor for stroke and mortality: A prospective follow-up study. Atherosclerosis 293, 79\u201385 (2020).","journal-title":"Atherosclerosis"},{"key":"2144_CR49","doi-asserted-by":"crossref","first-page":"E3545","DOI":"10.3390\/nu12113545","volume":"12","author":"A Lamaziere","year":"2020","unstructured":"Lamaziere, A. et al. Distinct postprandial bile acids responses to a high-calorie diet in men volunteers underscore metabolically healthy and unhealthy phenotypes. Nutrients 12, E3545 (2020).","journal-title":"Nutrients"},{"key":"2144_CR50","doi-asserted-by":"crossref","unstructured":"Remely, M. et al. Gut microbiota of obese, type 2 diabetic individuals is enriched in Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus anaerobius after weight loss. Endocr. Metab. Immune Disord. Drug Targets (2016).","DOI":"10.2174\/1871530316666160831093813"},{"key":"2144_CR51","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1093\/eurheartj\/ehx342","volume":"38","author":"GG Schiattarella","year":"2017","unstructured":"Schiattarella, G. G. et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. Eur. Heart J. 38, 2948\u20132956 (2017).","journal-title":"Eur. Heart J."},{"key":"2144_CR52","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12944-018-0939-6","volume":"17","author":"L Ding","year":"2018","unstructured":"Ding, L. et al. Trimethylamine-N-oxide (TMAO)-induced atherosclerosis is associated with bile acid metabolism. Lipids Health Dis. 17, 286 (2018).","journal-title":"Lipids Health Dis."},{"key":"2144_CR53","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/eji.201646879","volume":"48","author":"S Ascher","year":"2018","unstructured":"Ascher, S. & Reinhardt, C. The gut microbiota: An emerging risk factor for cardiovascular and cerebrovascular disease. Eur. J. Immunol. 48, 564\u2013575 (2018).","journal-title":"Eur. J. Immunol."},{"key":"2144_CR54","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ncomms2266","volume":"3","author":"FH Karlsson","year":"2012","unstructured":"Karlsson, F. H. et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat. Commun. 3, 1245 (2012).","journal-title":"Nat. Commun."},{"key":"2144_CR55","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1073\/pnas.1011383107","volume":"108","author":"O Koren","year":"2011","unstructured":"Koren, O. et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc. Natl. Acad. Sci. USA 108, 4592\u20134598 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2144_CR56","doi-asserted-by":"crossref","unstructured":"Humbert, L. et al. Bile acid profiling in human biological samples: comparison of extraction procedures and application to normal and cholestatic patients. J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci. 899, 135\u2013145 (2012).","DOI":"10.1016\/j.jchromb.2012.05.015"},{"key":"2144_CR57","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/gb-2012-13-9-r79","volume":"13","author":"XC Morgan","year":"2012","unstructured":"Morgan, X. C. et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 13, R79 (2012).","journal-title":"Genome Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02144-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02144-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02144-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T17:33:04Z","timestamp":1670088784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02144-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2144"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-02144-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"4 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Chong-Nguyen reports grants from Federation fran\u00e7aise de cardiologie, during the conduct of the study Pr Denis Duboc reports personal fees from Pfizer, personal fees from Takeda, personal fees from Wawe life science, personal fees from Amgen, personal fees from Novartis, outside the submitted work; Dr Dominique Rainteau has no conflict of interest to declare Pr Harry Sokol reports personal fees from Danone, grants from Biocodex, personal fees from MSD, personal fees from Takeda, personal fees from Abbvie, personal fees from Astellas, other from Enterome, other from Maat, personal fees from Novartis, personal fees from BMS, outside the submitted work. Mrs Lydie Humbert has no conflict of interest to declare Pr Philippe Seksik has no conflict of interest to declare Mrs Ad\u00e8le Bellino has no conflict of interest to declare Dr Hendy Abdoul has no conflict of interest to declare Dr Naim Bouazza has no conflict of interest to declare Pr Jean Marc Treluyer has no conflict of interest to declare Dr Malikaa Saadi has no conflict of interest to declare Dr Karim Wahbi has no conflict of interest to declare Dr Heithem Soliman has no conflict of interest to declare Pr. Benoit Coffin reports personal fees from Mayoly Spindler, personal fees from Kyowa Kirin, personal fees from Ipsen, personal fees from Mundipharma, personal fees from Abbott, outside the submitted work Dr Andr\u00e9 Bado has no conflict of interest to declare Dr Maude Le Gall has no conflict of interest to declare Pr Olivier Varenne reports grants and personal fees from Boston Scientific, personal fees from Astra Zeneca, personal fees from Abbott Vascular, personal fees from Servier, outside the submitted work Dr. Henri Duboc reports grants from FEDERATION FRANCAISE DE CARDIOLOGIE, from null, during the conduct of the study; personal fees from BIOCODEX, grants from SNFGE, outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22661"}}